PE20160039A1 - NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA - Google Patents

NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA

Info

Publication number
PE20160039A1
PE20160039A1 PE2015002323A PE2015002323A PE20160039A1 PE 20160039 A1 PE20160039 A1 PE 20160039A1 PE 2015002323 A PE2015002323 A PE 2015002323A PE 2015002323 A PE2015002323 A PE 2015002323A PE 20160039 A1 PE20160039 A1 PE 20160039A1
Authority
PE
Peru
Prior art keywords
pyrimidine
pyrrolo
pirrolo
new derivatives
pyrrolidin
Prior art date
Application number
PE2015002323A
Other languages
English (en)
Inventor
Mark Rogers-Evans
Stephan Roever
Tanja Schulz-Gasch
Atsushi Kimbara
Matthias Nettekoven
Uwe Grether
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160039A1 publication Critical patent/PE20160039A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Referida a un compuesto derivado de pirrolo[2,3-d]pirimidina de formula (I), donde A es CH2 o esta ausente; R1 y R2 junto con el atomo de nitrogeno, al que estan unidos, forman un pirrolidinilo sustituido, etc; R3 es halogeno, etc. Dichos compuestos son agonistas de los receptores canabinoides. Son compuestos preferidos: 2-tert-butil-7-[2-clorofenil)metil]-4-(3,3-difluor-pirrolidin-1-il)pirrolo[2,3-d]pirimidina; 2-tert-butil-7-[2-cloro-4-fluorfenil)metil]-4-(3,3-difluor-pirrolidin-1-il)pirrolo[2,3-d]pirimidina, entre otros
PE2015002323A 2013-05-02 2014-04-29 NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA PE20160039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02

Publications (1)

Publication Number Publication Date
PE20160039A1 true PE20160039A1 (es) 2016-01-28

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002323A PE20160039A1 (es) 2013-05-02 2014-04-29 NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA

Country Status (35)

Country Link
US (1) US9580435B2 (es)
EP (1) EP2991988B1 (es)
JP (1) JP6454689B2 (es)
KR (1) KR20160002857A (es)
CN (1) CN105164133B (es)
AR (1) AR096153A1 (es)
AU (1) AU2014261546B2 (es)
BR (1) BR112015027394A8 (es)
CA (1) CA2907691A1 (es)
CL (1) CL2015003196A1 (es)
CR (1) CR20150555A (es)
CY (1) CY1119114T1 (es)
DK (1) DK2991988T3 (es)
EA (1) EA028123B1 (es)
ES (1) ES2635632T3 (es)
HK (1) HK1213559A1 (es)
HR (1) HRP20171099T1 (es)
HU (1) HUE035333T2 (es)
IL (1) IL242162B (es)
LT (1) LT2991988T (es)
MA (1) MA38555B1 (es)
MX (1) MX2015014081A (es)
MY (1) MY182237A (es)
NZ (1) NZ712030A (es)
PE (1) PE20160039A1 (es)
PH (1) PH12015502409A1 (es)
PL (1) PL2991988T3 (es)
PT (1) PT2991988T (es)
RS (1) RS56313B1 (es)
SG (1) SG11201509029PA (es)
SI (1) SI2991988T1 (es)
TW (1) TWI680129B (es)
UA (1) UA116801C2 (es)
WO (1) WO2014177527A1 (es)
ZA (1) ZA201507008B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2714094T3 (es) 2013-09-06 2019-05-27 Hoffmann La Roche Derivados de triazolo[4,5-d]pirimidina como antagonistas del receptor cb2
EA031735B1 (ru) * 2014-11-07 2019-02-28 Ф. Хоффманн-Ля Рош Аг ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
JP6964099B2 (ja) 2016-06-23 2021-11-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン誘導体
CN113943297A (zh) 2016-06-23 2022-01-18 豪夫迈·罗氏有限公司 对2型大麻素受体具有亲和力的[1,2,3]三唑并[4,5-d]嘧啶衍生物
CN109415366B (zh) 2016-06-23 2022-02-22 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR042667A1 (es) * 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
MX2008012400A (es) * 2006-03-30 2008-10-10 Irm Llc Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
EP2155747B1 (en) * 2007-05-10 2012-10-24 GE Healthcare Limited Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
US20090062253A1 (en) * 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009051705A1 (en) 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
AP2012006192A0 (en) * 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
EA025840B1 (ru) 2012-12-07 2017-02-28 Ф. Хоффманн-Ля Рош Аг Производные пиразина в качестве агонистов каннабиноидного рецептора 2
MX2015007155A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Nuevos derivados de piridina.
PT2928867T (pt) 2012-12-07 2017-10-04 Hoffmann La Roche Piridinas-2-amidas úteis como agonistas de cb2
LT2928868T (lt) 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
HUE034831T2 (en) 2013-03-07 2018-03-28 Hoffmann La Roche New pyrazole derivatives
MA38460B1 (fr) 2013-05-02 2017-10-31 Hoffmann La Roche Dérivés de la purine en tant qu'agonistes du récepteur cb2

Also Published As

Publication number Publication date
DK2991988T3 (en) 2017-08-21
ZA201507008B (en) 2017-08-30
MA38555B1 (fr) 2018-04-30
CA2907691A1 (en) 2014-11-06
AR096153A1 (es) 2015-12-09
PL2991988T3 (pl) 2017-10-31
HUE035333T2 (en) 2018-05-02
CR20150555A (es) 2015-11-20
EA201591939A1 (ru) 2016-03-31
SI2991988T1 (sl) 2017-09-29
SG11201509029PA (en) 2015-12-30
TW201522343A (zh) 2015-06-16
TWI680129B (zh) 2019-12-21
EP2991988B1 (en) 2017-05-31
BR112015027394A8 (pt) 2018-01-30
ES2635632T3 (es) 2017-10-04
PT2991988T (pt) 2017-07-25
US9580435B2 (en) 2017-02-28
KR20160002857A (ko) 2016-01-08
EP2991988A1 (en) 2016-03-09
PH12015502409B1 (en) 2016-02-22
CN105164133B (zh) 2018-02-13
HRP20171099T1 (hr) 2017-10-06
HK1213559A1 (zh) 2016-07-08
MY182237A (en) 2021-01-18
PH12015502409A1 (en) 2016-02-22
RS56313B1 (sr) 2017-12-29
IL242162B (en) 2019-06-30
JP2016517874A (ja) 2016-06-20
LT2991988T (lt) 2017-08-10
BR112015027394A2 (pt) 2017-07-25
WO2014177527A1 (en) 2014-11-06
JP6454689B2 (ja) 2019-01-16
NZ712030A (en) 2021-03-26
MX2015014081A (es) 2015-12-11
CL2015003196A1 (es) 2016-06-03
AU2014261546A1 (en) 2015-09-24
US20160046637A1 (en) 2016-02-18
CY1119114T1 (el) 2018-02-14
UA116801C2 (uk) 2018-05-10
CN105164133A (zh) 2015-12-16
MA38555A1 (fr) 2017-09-29
AU2014261546B2 (en) 2018-01-18
EA028123B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
PE20160039A1 (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
PE20151977A1 (es) Nuevos derivados de purina
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
IN2014MN01897A (es)
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
CY1111125T1 (el) Υποκατεστημενα παραγωγα δικυκλικης πυριμιδονης
UY32296A (es) Nuevos compuestos
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
TR201900662T4 (tr) Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri.
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
PE20170683A1 (es) Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
AR091185A1 (es) Derivados de 1,2,4-triazol
CO6270226A2 (es) Nuevos compuestos espirociclicos como antagonistas de cgrp

Legal Events

Date Code Title Description
FG Grant, registration